Pacira Pharma (PCRX) Posts Wider than Expected Loss; Reiterates FY11 Outlook

Pacira Pharmaceuticals Inc. (NASDAQ: PCRX) reported Q1 loss of $0.98, $0.45 worse than the analyst estimate of ($0.53). Revenue for the quarter came in at $3.9 million versus the consensus estimate of $4.16 million.

Reiterates FY11 revs outlook.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• L3Harris Technologies (LHX) Tops Q1 EPS by 15c; raises guidance
• Utah Medical Products (UTMD) Reports Q1 EPS of $1.10
• Data I/o Corp (DAIO) Misses Q2 EPS by 7c